Chiltern seeking metabolism expertise for new unit after hiring ex PPD exec

By Dan Stanton

- Last updated on GMT

Chiltern seeking metabolism expertise for new unit after hiring ex PPD exec

Related tags Insulin Diabetes mellitus type 2 Obesity

Got experience in endocrinology and metabolism indications R&D? Chiltern has added a new offering and says it is looking to hire.

Chiltern’s acquisition of Theorem​ last month strengthened its oncology, biopharma, medical device and diagnostic offerings, creating what the firm said is the largest mid-sized contract research organisation (CRO).

Now the firm says it is expanding its business further to include endocrine and metabolism services through the addition of Randy Anderson as senior vice president of scientific affairs.

“My experience and expertise in strategic program design for endocrine and metabolism products will be a new service offering at Chiltern,”​ Anderson, who has nearly 30 years of industry experience in the industry, told Outsourcing-Pharma.

My hire is synergistic with the recent Theorem acquisition in expanding Chiltern’s capacity for design and execution of endocrinology and metabolism programs.”

For the past five years, Anderson served as Vice President of Global Product Development for Metabolics at PPD, and before that spent twelve years at the Big CRO in senior management roles.

He is now looking to help Chiltern respond to client demand by expanding its clinical services for endocrinology and metabolism, and said the firm is looking for further expertise:

Chiltern is actively hiring management and operations staff with experience in endocrinology and metabolism indications,”​ he told us.

This include: “Type 2 diabetes, type 1 diabetes, diabetes complications, nonalcoholic steatohepatitis, obesity, dyslipidemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more